Re: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09.
Pritsos
C
C
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001388:Aziridines / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D045563:Indolequinones; D007211:Indoles / Q000494:pharmacology*; D016685:Mitomycin / Q000494:pharmacology*; D009316:National Institutes of Health (U.S.); D010088:Oxidoreductases / Q000096:biosynthesis* / Q000187:drug effects / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000201:enzymology*; D014481:United States
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; D016685:Mitomycin; D010088:Oxidoreductases; C060817:apaziquone